Guardant Health, Inc. filings document a Nasdaq-listed precision oncology company that reports results for Oncology, Screening, and Biopharma & Data activities. Its 8-K filings furnish quarterly and annual financial results, preliminary financial information, Regulation FD presentation materials, material agreements, officer changes, and securities offering disclosures.
The company’s proxy materials cover annual meeting voting matters, board and governance information, executive compensation and stockholder proposals. Registration and offering-related filings describe common stock issuance under a shelf registration statement, while recurring disclosures address capital structure, operating outlook, clinical and regulatory updates, and the use of its blood and tissue testing portfolio.
Guardant Health, Inc. director Vijaya Gadde reported routine equity compensation activity. On June 17, 2026, Gadde exercised restricted stock units covering 4,203 shares of Common Stock, increasing direct holdings to 28,517 shares. On the same date, Gadde also received a new award of 2,711 restricted stock units that will vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the company’s next annual meeting of stockholders.
Guardant Health director Ian T. Clark reported equity compensation activity tied to the 2026 Annual Meeting of Stockholders. A previously granted restricted stock unit (RSU) award vested in full on June 17, 2026 and was exercised into 5,092 shares of common stock, bringing indirect holdings in a family trust to 8,067 shares.
Clark also received a new grant of 2,711 RSUs on June 17, 2026. These RSUs convert into the same number of common shares and are scheduled to vest in full on the one-year anniversary of the grant date or on the date of Guardant Health’s next annual stockholder meeting, whichever occurs earlier. All reported transactions are acquisitions related to awards rather than open-market buying or selling.
Azar Alex M II reported acquisition or exercise transactions in this Form 4 filing.
Guardant Health director Azar Alex M II received a grant of 2,711 Restricted Stock Units (RSUs) tied to the company’s common stock. Each RSU represents the right to receive one share of common stock for no cash payment. The award vests in full on June 17, 2026, the one-year anniversary of the grant date, or on the date of Guardant Health’s next annual meeting of stockholders, whichever occurs earlier. Following this Form 4 transaction, Azar holds 2,711 RSUs directly.
Guardant Health filed a Form 144 disclosing restricted stock lapses and related sales by an individual. The filing lists three reported transactions by Musa Tariq on 04/16/2026 (9,840.00), 05/18/2026 (11,131.00), and 06/16/2026 (15,102.00) tied to equity compensation and a restricted stock lapse dated 06/18/2026.
Guardant Health, Inc. notice of proposed sales under Form 144 by an affiliate. The filing lists an employee stock option exercise of 2,000 shares settled via a broker payment for a cashless exercise on 06/22/2026, a restricted stock lapse of 4,203 shares on 06/17/2026, and a reported sale of 10,000 shares on 06/03/2026 for $1,269,809.00.
Guardant Health, Inc. reported results of its June 17, 2026 annual stockholder meeting. Stockholders elected all director nominees, including Ian Clark with 70,526,891 votes for and Manuel Hidalgo Medina with 81,925,123 votes for, with broker non-votes recorded on each.
Stockholders approved the ratification of Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026, with 115,899,030 votes for. An advisory vote to approve compensation of named executive officers was not approved, receiving 98,236,639 votes for and 9,905,190 votes against. In an advisory vote on the frequency of future say-on-pay votes, most votes were cast for one year, with 107,997,996 votes for that option.
Guardant Health Chief Information Officer Kumud Kalia reported routine stock-based compensation activity. On June 15, 2026, 638 restricted stock units converted into common shares, while 314 shares were withheld by the company to cover tax obligations. After these transactions, Kalia directly holds 41,414 common shares.
Guardant Health director Tariq Musa reported a small mix of stock transactions involving company shares. On June 15, 2026, a restricted stock unit (RSU) award converted into 250 shares of common stock at a stated price of $0.00 per share, reflecting vesting of previously granted equity compensation.
The same RSU award was originally granted on March 6, 2023 and vests over four years, with 25% vesting on March 15, 2024 and the remaining 75% vesting monthly over three years. On June 16, 2026, Musa executed an open-market sale of 116 shares of common stock at an average price of $130.19 per share. Following these transactions, he holds 8,796 shares of Guardant Health common stock directly.
Guardant Health Chief Legal Officer John G. Saia reported compensation-related stock activity on June 15, 2026. He exercised 1,020 restricted stock units into common shares, then had 535 of those shares withheld by the company at $129.82 per share to cover tax obligations, with no open-market sale. After these transactions, Saia directly holds 36,435 Guardant Health shares. The RSU award was granted on June 9, 2023 and vests over three years, with 33% vesting on June 15, 2024 and the remaining 67% vesting in equal quarterly installments over the following two years.